Evidence map›Paper›PMID 29684428›Full record

ArticleJournal of immunological methods2018

Validation of a CD1b tetramer assay for studies of human mycobacterial infection or vaccination.

Erik D Layton, Krystle K Q Yu, Malisa T Smith, Thomas J Scriba, Stephen C De Rosa, Chetan Seshadri

Abstract readValidation Study
In one paragraph

Article in Journal of immunological methods, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. International journal of molecular sciences · 2021
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Erik D LaytonDepartment of Medicine, University of Washington, Seattle, WA, USA.
Krystle K Q YuDepartment of Medicine, University of Washington, Seattle, WA, USA.
Malisa T SmithDepartment of Medicine, University of Washington, Seattle, WA, USA.
Thomas J ScribaSouth African Tuberculosis Vaccine Initiative and Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Stephen C De RosaDepartment of Laboratory Medicine, University of Washington, Seattle, WA, USA; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Chetan SeshadriDepartment of Medicine, University of Washington, Seattle, WA, USA. Electronic address: seshadri@u.washington.edu.
University of Washington · USInfectious Disease Research Institute · USUniversity of Cape Town · ZA

Funding

LC: HIV Vaccine Trials NetworkUM1AI068618 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Margaret Juliana McElrath · 2011 to 2026
$483.6M
University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI Kenneth Sherr · 1988 to 2026
$104.9M
Qualification of Assays to Measure Human T-cell Responses Against Mycobacterial Lipid AntigensR01AI125189 · NIAID · UNIVERSITY OF WASHINGTON · PI SESHADRI, CHETAN · 2016 to 2020
$3.1M
Doris Duke Charitable Foundation 2016103NIAID NIH HHS P30 AI027757NIAID NIH HHS R01 AI125189NIAID NIH HHS UM1 AI068618
6 · The paper itself

Abstract

CD1 tetramers loaded with lipid antigens facilitate the identification of rare lipid-antigen specific T cells present in human blood and tissue. Because CD1 proteins are structurally non-polymorphic, these tetramers can be applied to genetically diverse human populations, unlike MHC-I and MHC-II tetramers. However, there are no standardized assays to quantify and characterize lipid antigen-specific T cells present within clinical samples. We incorporated CD1b tetramers loaded with the mycobacterial lipid glucose monomycolate (GMM) into a multi-parameter flow cytometry assay. Using a GMM-specific T-cell line, we demonstrate that the assay is linear, reproducible, repeatable, precise, accurate, and has a limit of detection of approximately 0.007%. Having formally validated this assay, we performed a cross-sectional study of healthy U.S. controls and South African adolescents with and without latent tuberculosis infection (LTBI). We show that GMM-specific T cells are specifically detected in South African subjects with LTBI and not in U.S. healthy controls. This assay can be expanded to include additional tetramers or phenotypic markers to characterize GMM-specific T cells in studies of mycobacterial infection, disease, or vaccination.

Indexed as

AdolescentAdultAntigens, BacterialAntigens, CD1Cell Culture TechniquesCell LineCross-Sectional StudiesEpitopes, T-LymphocyteFlow CytometryGlycolipidsHealthy VolunteersHumansImmunogenicity, VaccineLatent TuberculosisMycobacterium tuberculosisProtein MultimerizationAntigens, BacterialAntigens, CD1CD1b antigenEpitopes, T-Lymphocyteglucose mycolateGlycolipidsTuberculosis VaccinesAssay validationCD1bHumanMycobacteriaT cellsTetramer

Identifiers

PMID29684428
PMCPMC5960426
OpenAlexW2801287671

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.